Global Contract Development and Manufacturing Organization (CDMO) Market to Reach New Heights by 2032, Driven by Outsourcing Demand, Biologic Expansion, and Specialized Capabilities | DelveInsight

The global CDMO market is witnessing sustained growth, propelled by the rising trend of pharmaceutical and biotech companies outsourcing development and manufacturing operations to enhance efficiency, reduce time-to-market, and manage costs. As the demand for complex biologics, cell and gene therapies, and specialized small molecules increases, CDMOs are evolving from simple service providers to strategic, end-to-end partners in the drug development lifecycle.

CDMOs offer a broad suite of services, including drug substance and product development, formulation, analytical testing, clinical trial supply, and commercial-scale manufacturing. The market encompasses both small-molecule and biologics CDMOs, with the latter gaining significant traction due to the growing pipeline of monoclonal antibodies, biosimilars, vaccines, and advanced therapy medicinal products (ATMPs). Companies are increasingly seeking partners with expertise in high-potency manufacturing, sterile fill-finish, and scalable production platforms.

DelveInsight's CDMO Market Insights, Competitive Landscape, and Market Forecast - 2032 provides an in-depth evaluation of market trends, regional dynamics, service segmentation, and evolving customer demands across key geographies, including North America, Europe, Asia-Pacific, and emerging markets. The report categorizes the market by molecule type, service offering, therapeutic area, and outsourcing models (contract development, contract manufacturing, or integrated CDMO services).

Major players such as Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, WuXi AppTec, Boehringer Ingelheim BioXcellence, and Fujifilm Diosynth Biotechnologies are making substantial investments in advanced manufacturing technologies, digitalization, modular facilities, and geographic expansion. Strategic mergers, acquisitions, and long-term partnerships are reshaping the competitive landscape, fostering innovation and flexibility in service delivery.

With increasing pipeline complexity, regulatory scrutiny, and the need for speed-to-market, CDMOs are set to play a central role in the future of pharmaceutical manufacturing. The market is poised for robust growth through 2032, anchored by a shift toward integrated, agile, and specialized outsourcing solutions focused on quality, scalability, and global reach.

Explore the latest trends and growth drivers in the contract development manufacturing organization market-download your sample report now https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Contract Development Manufacturing Organization Market Report
• The global CDMO market was valued at USD 233.71 billion in 2024 and is projected to grow at a CAGR of 7.25% from 2025 to 2032, reaching an estimated USD 407.09 billion by 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the global contract development manufacturing organization market during the forecast period.
• Notable contract development manufacturing organization companies such as Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics, and several others are currently operating in the contract development manufacturing organization market.
• In May 2025, Lupin Manufacturing Solutions (LMS) announced the relegation of its core assets and long-term vision to capitalize on emerging opportunities in the CDMO space. By investing in innovative treatment platforms and harnessing the strength of India's robust API ecosystem, LMS aimed to enhance its capabilities and drive sustainable growth in the global contract development and manufacturing market.
• In May 2025, VGXI, Inc., a CDMO specializing in plasmid DNA for gene therapies and vaccines, successfully completed a US FDA inspection at its GMP facility, leading to approval of a client's Biologics License Application (BLA). This milestone highlights VGXI's commitment to quality and regulatory excellence.
• In May 2025, Tivic Health® Systems, Inc. announced a definitive agreement with Scorpius BioManufacturing to complete GMP manufacturing validation of EntolimodTM, its lead TLR5 candidate for Acute Radiation Syndrome (ARS), in preparation for a BLA filing with the FDA.
• In March 2025, Ayrmid Pharma Ltd. and RoslinCT announced plans to form a strategic partnership for the production of Omisirge, a cell therapy used to treat hematologic malignancies and commercialized in the U.S. by Ayrmid's subsidiary, Gamida Cell Inc.

To read more about the latest highlights related to the contract development manufacturing organization market, get a snapshot of the key highlights entailed in the global contract development manufacturing organization market report here https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Contract Development Manufacturing Organization Overview
Contract Development and Manufacturing Organizations (CDMOs) are specialized service providers that support pharmaceutical and biotechnology companies in the development and manufacturing of drug substances and drug products. They offer a wide range of services, including formulation development, process optimization, analytical testing, clinical trial material production, and commercial-scale manufacturing. CDMOs enable companies to outsource critical stages of the drug development lifecycle, allowing sponsors to reduce costs, accelerate timelines, and focus on core R&D and commercialization strategies. This model is especially valuable for small to mid-sized biopharma companies that may lack in-house infrastructure and capabilities.

The CDMO market has evolved significantly in recent years, driven by increasing demand for complex therapeutics such as biologics, cell and gene therapies, and high-potency small molecules. Modern CDMOs are adopting advanced technologies like continuous manufacturing, single-use bioreactors, and AI-based process optimization to deliver flexible, scalable, and high-quality solutions. Strategic collaborations, long-term partnerships, and integrated service offerings are now central to the CDMO business model. As the pharmaceutical industry continues to globalize and innovate, CDMOs are playing an increasingly vital role in enhancing supply chain agility, meeting regulatory requirements, and ensuring faster and more efficient drug development and commercialization.

Contract Development Manufacturing Organization Market Insights
North America is expected to dominate the global CDMO market in 2024, driven by a rising burden of chronic diseases such as cancer and tuberculosis, and a growing trend among pharmaceutical and biotech companies to outsource development and manufacturing. Outsourcing to CDMOs helps reduce costs, enhance operational efficiency, and accelerate time-to-market-factors that are increasingly crucial amid growing demand for innovative and personalized therapies.

According to the National Cancer Institute, an estimated 2 million new cancer cases will be diagnosed in the US in 2024. In 2022, the Global Cancer Observatory reported that the US accounted for 89.1% of all cancer cases in North America, with Canada at 10.9%. The region's high disease burden, especially in oncology, is driving demand for specialized CDMO services in biologics manufacturing, molecular diagnostics, and personalized medicine. Supporting this growth are strategic moves by industry leaders, such as Lonza's 2024 restructuring to focus on its core CDMO platforms-Integrated Biologics, Advanced Synthesis, and Specialized Modalities-starting in Q2 2025, signaling an intensified focus on high-value, scalable therapeutic production across the region.

To know more about why North America is leading the market growth in the Contract Development Manufacturing Organization market, get a snapshot of the Contract Development Manufacturing Organization market outlook here https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Contract Development Manufacturing Organization Market Dynamics
According to the World Health Organization (2024) and IARC, nearly 20 million new cancer cases were reported globally in 2022, with lung cancer (2.5M), breast cancer (2.3M), colorectal cancer (1.9M), and stomach cancer (0.97M) leading the global incidence. This growing cancer burden is accelerating the demand for advanced oncology therapies, prompting pharmaceutical and biotech companies to increasingly rely on CDMOs for specialized drug development, scale-up, and manufacturing of complex therapies like biologics and ADCs.

The rising demand for biologics and small-molecule drugs-which require advanced infrastructure and regulatory compliance-is a key growth driver for the CDMO market. Leading CDMOs like Lonza, Samsung Biologics, and Catalent are capitalizing on this trend. For example, in October 2024, Samsung Biologics signed a $1.24 billion contract with an Asia-based pharma firm, its largest single-client deal, pushing its annual contract value beyond $3.3 billion. However, the market still faces challenges, particularly regulatory complexities that can delay product approvals. Despite this, the global CDMO market is expected to see strong growth from 2025 to 2032, driven by innovation, outsourcing trends, and increasing demand for specialized manufacturing.

Get a sneak peek at the contract development manufacturing organization market dynamics @ https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coverage: Global
Study Period: 2022 to 2032
Contract Development Manufacturing Organization Market CAGR: ~6.25%
Key Contract Development Manufacturing Organization Companies: Patheon (Thermo Fisher Scientific), Catalent, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics, and others.

Contract Development Manufacturing Organization Market Segmentation
Market Segmentation By Drug Type: Small Molecules and Biologics.
Market Segmentation By Service Type: API and Finished Drug Products.
Market Segmentation By Forms: Solids and Liquids.
Market Segmentation By Manufacturing: Clinical Manufacturing and Commercial Manufacturing
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.

Which MedTech key players in the contract development manufacturing organization market are set to emerge as the trendsetter, explore @ https://www.delveinsight.com/report-store/contract-development-manufacturing-organization-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Contract Development Manufacturing Organization Market Report Introduction
2. Contract Development Manufacturing Organization Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Contract Development Manufacturing Organization Market Key Factors Analysis
6. Contract Development Manufacturing Organization Market Porter's Five Forces Analysis
7. Contract Development Manufacturing Organization Market Layout
8. Contract Development Manufacturing Organization Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.